



BEST AVAILABLE COPY

FORM PTO-1449 (Modified)		Attorney Docket No.: 015280-415100US		Application No.: 09/810,310			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Samir Khleif <i>et al.</i>					
		Filing Date: March 14, 2001		Group: 1644			
Reference Designation		U.S. PATENT DOCUMENTS				Page 1 of 1	
Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
	AA.	4,599,230	July 8, 1986	Milich <i>et al.</i>			
	AB.	4,599,231	July 8, 1986	Milich <i>et al.</i>			
	AC.	5,861,310	Jan. 19, 1999	Freeman <i>et al.</i>			
	AD.	5,866,553	Feb. 2, 1999	Donnelly <i>et al.</i>			
	AE.	5,942,607	Aug. 24, 1999	Freeman <i>et al.</i>			
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
	my AF.	90/11092	Oct. 4, 1990	WO			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
MO	AG.	Acsadi <i>et al.</i> , "Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs," <i>Nature</i> 352:815-818 (1991)					
MO	AH.	Aichele <i>et al.</i> , "Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide," <i>J. Exp. Med.</i> 171:1815-1820 (1990)					
MO	AI.	Armitage <i>et al.</i> , "Molecular and biological characterization of a murine ligand for CD40," <i>Nature</i> 357:80-82 (1992)					
MO	AJ.	Azuma <i>et al.</i> , "B70 antigen is a second ligand for CTLA-4 and CD28," <i>Nature</i> 366:76-79 (1993)					
MO	AK.	Baskar <i>et al.</i> , "Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules," <i>Proc. Natl. Acad. Sci. USA</i> 90:5687-5690 (1993)					
MO	AL.	Bleijs <i>et al.</i> , "Co-stimulation of T cells results in distinct IL-10 and TNF- α cytokine profiles dependent on binding to ICAM-1, ICAM-2 or ICAM-3," <i>Eur. J. Immunol.</i> 29:2248-2258 (1999)					
MO	AM.	Boon, T., "Toward a genetic analysis of tumor rejection antigens," <i>Adv. Cancer Res.</i> 58:177-210 (1992)					
MO	AN.	Bretscher and Cohn, "A theory of self-nonself discrimination," <i>Science</i> 169:1042-1049 (1970)					
MO	AO.	Brodsky <i>et al.</i> , "Antigen processing and presentation," <i>Tissue Antigens</i> 47:464-471 (1996)					
MO	AP.	Brunet <i>et al.</i> , "A new member of the immunoglobulin superfamily -- CTLA-4," <i>Nature</i> 328:267-270 (1987)					
MO	AQ.	Carpenito <i>et al.</i> , "ICAM-2 provides a costimulatory signal for T cell stimulation by allogeneic class II MHC," <i>Scand. J. Immunol.</i> 45:248-254 (1997)					
MO	AR.	Chang <i>et al.</i> , "Heterogeneity in direct cytotoxic function of L3T4 T cells - TH1 clones express higher cytotoxic activity to antigen-presenting cells than TH2 clones," <i>J. Immunol.</i> 145:409-416 (1990)					
MO	AS.	Chen <i>et al.</i> , "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4," <i>Cell</i> 71:1093-1102 (1992)					
MO	AT.	Dong <i>et al.</i> , "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," <i>Nat. Med.</i> 5:1365-1369 (1999)					

Manana
11/18/04

FORM PTO-1449 (Modified)		Attorney Docket No.: 015280-415100US	Application No.: 09/810,310
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Samir Khleif <i>et al.</i>	
		Filing Date: March 14, 2001	Group: 1644

NO	AU.	Dustin <i>et al.</i> , "Correlation of CD2 binding and functional properties of multimeric and monomeric lymphocyte function-associated antigen 3," <i>J. Exp. Med.</i> 169:503-517 (1989)
NO		Eisenlohr <i>et al.</i> , "A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes," <i>J. Immunol. Meth.</i> 154:131-138 (1992)
NO		Elliott <i>et al.</i> , "Perspectives on the role of MHC antigens in normal and malignant cell development," <i>Adv. Cancer Res.</i> 53:181-245 (1989)
NO	AX.	Fearon <i>et al.</i> , "Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response," <i>Cell</i> 60:397-403 (1990)
NO	AY.	Freeman <i>et al.</i> , "Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7," <i>J. Exp. Med.</i> 174:625-631 (1991)
NO	AZ.	Fynan <i>et al.</i> , "DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations," <i>Proc. Natl. Acad. Sci. USA</i> 90:11478-11482 (1993)
NO	BA.	Gansbacher <i>et al.</i> , "Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity," <i>J. Exp. Med.</i> 172:1217-1224 (1990)
NO	BB.	Germain, R., "The ins and outs of antigen processing and presentation," <i>Nature</i> 322:687-691 (1986)
NO	BC.	Gimmi <i>et al.</i> , "B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2," <i>Proc. Natl. Acad. Sci. USA</i> 88:6575-6579 (1991)
NO	BD.	Gimmi <i>et al.</i> , "Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation," <i>Proc. Natl. Acad. Sci. USA</i> 90:6586-6590 (1993)
NO	BE.	Golumbek <i>et al.</i> , "Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4," <i>Science</i> 254:713-716 (1991)
NO	BF.	Greenberg, P. D., "Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells," <i>Adv. Immunol.</i> 49:281-355 (1991)
NO	BG.	Harding <i>et al.</i> , "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> 356:607-609 (1992)
NO	BH.	Hart <i>et al.</i> , "Priming of anti-human immunodeficiency virus (HIV) CD8 ⁺ cytotoxic T cells <i>in vivo</i> by carrier-free HIV synthetic peptides," <i>Proc. Natl. Acad. Sci. USA</i> 88:9448-9452 (1991)
NO	BI.	Harty <i>et al.</i> , "CD8 ⁺ T cells specific for a single nonamer epitope of <i>Listeria monocytogenes</i> are protective <i>in vivo</i> ," <i>J. Exp. Med.</i> 175:1531-1538 (1992)
NO	BJ.	Hellström and Hellström, in <i>The Biologic Therapy of Cancer</i> , pp. 35-52, Devita <i>et al.</i> , eds., Philadelphia, J. B. Lippincott Co. (1991)
NO	BK.	Hunt <i>et al.</i> , "Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-A ^d ," <i>Science</i> 256:1817-1820 (1992)
NO	BL.	Janeway, C.A., Jr., "Approaching the asymptote? Evolution and revolution in immunology," <i>Cold Spring Harbor Symp. Quant. Biol.</i> 54:1-13 (1989)
NO	BM.	Jenkins <i>et al.</i> , "Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells," <i>J. Immunol.</i> 140:3324-3330 (1988)
NO	BN.	June <i>et al.</i> , "Role of the CD28 receptor in T-cell activation," <i>Immunol. Today</i> 11:211-216 (1990)
NO	BO.	Kast <i>et al.</i> , "Protection against lethal Sendai virus infection by <i>in vivo</i> priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 88:2283-2287 (1991)
NO	BP.	Kotovuori <i>et al.</i> , "ICAM-2 and a peptide from its binding domain are efficient activators of leukocyte adhesion and integrin affinity," <i>J. Immunol.</i> 162:6613-6620 (1999)
NO	BQ.	Koulova <i>et al.</i> , "The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4 ⁺ T cells," <i>J. Exp. Med.</i> 173:759-762 (1991)
NO	BR.	Kripke, "Immunologic mechanisms in UV radiation carcinogenesis," <i>Adv. Cancer Res.</i> 34:69-75 (1981)
NO	BS.	Lafferty <i>et al.</i> , "Immunobiology of tissue transplantation: a return to the passenger leukocyte concept," <i>Ann. Rev. Immunol.</i> 1:143-173 (1983)

FORM PTO-1449 (Modified)		Attorney Docket No.: 015280-415100US	Application No.: 09/810,310
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Samir Khleif <i>et al.</i>	
		Filing Date: March 14, 2001	Group: 1644

JP 5	LaSalle <i>et al.</i> , "Presentation of autoantigen by human T cells," <i>J. Immunol.</i> 147:774-780 (1991)
NO	Lenschow <i>et al.</i> , "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig," <i>Science</i> 257:789-792 (1992)
NO	Ley <i>et al.</i> , "Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes <i>in vivo</i> ," <i>Eur. J. Immunol.</i> 21:851-854 (1991)
NO	Linsley <i>et al.</i> , "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1," <i>Proc. Natl. Acad. Sci. USA</i> 87:5031-5035 (1990)
NO	Linsley <i>et al.</i> , Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," <i>J. Exp. Med.</i> 173:721-730 (1991)
NO	Liu <i>et al.</i> , "Heat-stable antigen is a costimulatory molecule for CD4 T cell growth," <i>J. Exp. Med.</i> 175:437-445 (1992)
NO	McKisic <i>et al.</i> , "Cytolytic activity of murine CD4 ⁺ T cell clones correlates with IFN- γ production in mouse strains having a BALB/c background," <i>J. Immunol.</i> 150:3793-3805 (1993)
NO	Melief, C. J. M., "Tumor eradication of adoptive transfer of cytotoxic T lymphocytes," <i>Adv. Cancer Res.</i> 58:143-175 (1992)
NO	Mueller <i>et al.</i> , "Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy," <i>Ann. Rev. Immunol.</i> 7:445-480 (1989)
NO	Nabel <i>et al.</i> , "Site-specific gene expression <i>in vivo</i> by direct gene transfer into the arterial wall," <i>Science</i> 249:1285-1288 (1990)
NO	Nossal, G. J. V., "Immunologic tolerance: collaboration between antigen and lymphokines," <i>Science</i> 245:147-153 (1989)
NO	Ostrand-Rosenberg <i>et al.</i> , "Rejection of mouse sarcoma cells after transfection of MHC class II genes," <i>J. Immunol.</i> 144:4068-4071 (1990)
NO	Ozdemirli <i>et al.</i> , "The cytotoxic process of CD4 Th1 clones," <i>J. Immunol.</i> 149:1889-1895 (1992)
NO	Parra <i>et al.</i> , "The role of B7-1 and LFA-3 in costimulation of CD8 ⁺ T cells," <i>J. Immunol.</i> 158:637-642 (1997)
NO	Reiser <i>et al.</i> , "Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex," <i>Proc. Natl. Acad. Sci. USA</i> 89:271-275 (1992)
NO	Rock <i>et al.</i> , "Analysis of the association of peptides of optimal length to class I molecules on the surface of cells," <i>Proc. Natl. Acad. Sci. USA</i> 89:8918-8922 (1992)
NO	Rosenberg <i>et al.</i> , "A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes," <i>Science</i> 233:1318-1321 (1986)
NO	Rosenberg <i>et al.</i> , "Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes," <i>Ann. Rev. Immunol.</i> 4:681-709 (1986)
NO	Rötzschke <i>et al.</i> , "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells," <i>Nature</i> 348:252-254 (1990)
NO	Rudensky <i>et al.</i> , "Sequence analysis of peptides bound to MHC class II molecules," <i>Nature</i> 353:622-627 (1991)
NO	Salomon <i>et al.</i> , "Cutting edge: LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production," <i>J. Immunol.</i> 161:5138-5142 (1998)
NO	Schreiber <i>et al.</i> , "Unique tumor-specific antigens," <i>Ann. Rev. Immunol.</i> 6:465-483 (1988)
NO	Schulz <i>et al.</i> , "Peptide-induced antiviral protection by cytotoxic T cells," <i>Proc. Natl. Acad. Sci. USA</i> 88:991-993 (1991)
NO	Schwartz, "Acquisition of immunologic self-tolerance," <i>Cell</i> 57:1073-1081 (1989)
NO	Selvakumar <i>et al.</i> , "Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7," <i>Immunogenetics</i> 36:175-181 (1992)
NO	Staunton <i>et al.</i> , "Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families," <i>Cell</i> 52:925-933 (1988)
NO	Swallow <i>et al.</i> , "B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNF α ," <i>Immunity</i> 11:423-432 (1999)

FORM PTO-1449 (Modified)

Application No.: 09/810,310

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

Applicant: Samir Khleif *et al.*

Filing Date: March 14, 2001

Group: 1644

CU.	Thompson <i>et al.</i> , "CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines," <i>Proc. Natl. Acad. Sci. USA</i> 86:1333-1337 (1989)
	Townsend <i>et al.</i> , "Antigen recognition by class I-restricted T lymphocytes," <i>Ann. Rev. Immunol.</i> 7:601-624 (1989)
	Townsend <i>et al.</i> , "Tumor rejection after direct costimulation of CD8 ⁺ T cells by B7-transfected melanoma cells," <i>Science</i> 259:368-370 (1993)
	Turka <i>et al.</i> , "T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 89:11102-11105 (1992)
CY.	van-Seventer <i>et al.</i> , "The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells," <i>J. Immunol.</i> 144:4579-4586 (1990)
CZ.	Wallner <i>et al.</i> , "Primary structure of lymphocyte function-associated antigen 3 (LFA-3) - The ligand of the T lymphocyte CD2 glycoprotein," <i>J. Exp. Med.</i> 166:923-932 (1987)
DA.	Wingren <i>et al.</i> , "T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles," <i>Crit. Rev. Immunol.</i> 15:235-253 (1995)
DB.	Wolff <i>et al.</i> , "Direct gene transfer into mouse muscle <i>in vivo</i> ," <i>Science</i> 247:1465-1468 (1990)
DC.	Young <i>et al.</i> , "The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4 ⁺ T lymphocytes by human blood dendritic cells <i>in vitro</i> ," <i>J. Clin. Invest.</i> 90:229-237 (1992)

EXAMINER

DATE CONSIDERED

11/15/24

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MARIANNE DIERING, Ph.D.